---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-255494"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2022-09-30T23:59:59+00:00"
generated_at: "2026-06-23T06:23:44.171717+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Silverback Therapeutics terminates Seattle HQ lease effective Dec 31, 2022

## Summary
- Terminated lease for ~19,829 sq ft at 500 Fairview Ave N, Seattle; lease expires Dec 31, 2022.
- No termination fee payable to landlord; lease end contingent on new tenant lease now executed.
- Tenant remains responsible for all rent through Dec 31, 2022; must surrender premises in good condition.
- Silverback grants temporary license to new tenant (Approved Licensee) for premises before termination.
- Company discloses it is undergoing a corporate merger; tenant entity will survive and remain liable.

## SEC filing metadata
- accession: 0001193125-22-255494
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2022-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312522255494/0001193125-22-255494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312522255494/d596886d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-255494
- JSON: https://secwatch.observer/filing/0001193125-22-255494.json
- Plain text: https://secwatch.observer/filing/0001193125-22-255494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.